Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets innovative implantable visual prosthetics that enable blind individuals to achieve greater independence. The company’s lead product is the Argus® II Retinal Prosthesis System, which is currently being studied in a trial designed to test its safety and utility in individuals with dry age-related macular degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. For more information, visit the company’s website at www.secondsight.com.
Second Sight Medical Products (EYES) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- MissionIRNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
- Brera Holdings PLC’s (NASDAQ: BREA) Becomes Second Multi-Club Owner in Italy’s Serie B, Signaling Rising Investment Opportunity
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
- MissionIRNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports Q1 Fiscal 2026 Net Income of $18.1 Million on $81.3 Million Revenue